A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Table 2 Values of Vital Signs for Patients who met Criteria for Categorical Change

Parameter	Augmentation Treatment	Augmentation Baseline	Categorical Change Value	Categorical Change	Duration of Augmentation
Blood pressure (mm/Hg)
Patient 1	MPH	84/56	110/86	D	1 week
Patient 2	MPH	110/53	124/74	S & D	6 weeks
Patient 3	PBO	108/78	110/90	D	2 weeks
Pulse Rate (bpm)
Patient 1	MPH	84	114	P	2 weeks
Patient 2	PBO	78	112	P	2 weeks

Categorical change defined as follows: (1) for diastolic and systolic blood pressure, an increase of at least 5 mmHg to above the 95^th percentile based on age, gender, and height-adjusted National Institute of Health norms [15]; (2) for pulse, an increase of at least 25 to a value of at least 110. Abbreviations: MPH, methylphenidate; PBO placebo, D, met categorical change definition for diastolic blood pressure; S met categorical change definition for systolic blood pressure; P met categorical change definition for pulse.

ISSN: 1753-2000